PURO Ikosa-EPA Science Hub

PURO Ikosa-EPA Science Hub

What the science says about purified EPA

Large heart studies tested purified EPA and mixed EPA+DHA in people already taking statins. The results were not the same. Here is what the research found and how EPA works.

  • 25%lower risk of major cardiovascular events with purified EPA in REDUCE-IT2
  • Nosignificant difference in major cardiovascular events with mixed EPA+DHA in STRENGTH and OMEMI4,5
A smiling golden softgel and a friendly heart float above patterned ocean waves, with small fish swimming nearby.

Why scientists studied EPA: the risk statins leave behind

Statins lower LDL cholesterol and prevent many heart attacks and strokes. Even so, people on statins can still have a heart attack or stroke. About 1 in 4 people with heart or artery disease have high triglycerides even when their LDL cholesterol is under control.1 Researchers wanted to know whether an omega-3 could lower this remaining risk.

The evidence

Purified EPA vs mixed EPA+DHA

Four large trials gave omega-3s to people already on statins and counted heart attacks, strokes and other major cardiovascular events. The two trials of purified EPA lowered risk. The two trials of mixed EPA+DHA did not.

Risk of major cardiovascular events

Omega-3 compared with placebo, in people on statins. Hazard ratio with 95% confidence interval.

Forest plot of four omega-3 outcome trials Purified EPA: REDUCE-IT hazard ratio 0.75 (0.68 to 0.83) and JELIS 0.81 (0.69 to 0.95), both below 1, meaning lower risk. Mixed EPA plus DHA: STRENGTH 0.99 (0.90 to 1.09) and OMEMI 1.07 (0.82 to 1.40), both crossing 1, meaning no difference. No difference Purified EPA REDUCE-IT8,179 people, 4 g/day 0.75 (0.68–0.83) JELIS18,645 people, 1.8 g/day 0.81 (0.69–0.95) Mixed EPA+DHA STRENGTH13,078 people, 4 g/day 0.99 (0.90–1.09) OMEMI1,027 people, 1.8 g/day 1.07 (0.82–1.40) 0.60.81.01.21.4 Lower risk = better Higher risk HR (95% CI) No differencePurified EPAMixed EPA+DHAREDUCE-IT0.75 (0.68–0.83)8,179 people, 4 g/dayJELIS0.81 (0.69–0.95)18,645 people, 1.8 g/daySTRENGTH0.99 (0.90–1.09)13,078 people, 4 g/dayOMEMI1.07 (0.82–1.40)1,027 people, 1.8 g/day0.60.81.01.21.4Lower risk = betterHigher risk
Sources: REDUCE-IT2, JELIS3, STRENGTH4, OMEMI5,6. JELIS compared EPA plus statin with statin alone (no placebo).

How to read the chart

Square = the resultThe further left of the dashed line, the bigger the drop in risk.
Whole line on the left = real benefitFewer people had major cardiovascular events. This is purified EPA.
Line crosses the dashed line = no proven differenceThe trial could not show it worked better than placebo. This is mixed EPA+DHA.
Step 1 of 6

Two kinds of omega-3 were tested

Purified EPA softgel: EPA only.

Purified EPA

EPA ethyl ester on its own

Mixed omega-3 softgel: EPA and DHA together.

Mixed EPA+DHA

Two omega-3s combined

EPA DHA Illustration only

Keep scrolling to see each trial appear on the chart.

Step 2 of 6
Purified EPA

REDUCE-IT, 20192

Who
Adults on statins with heart disease, or diabetes plus risk factors, and raised triglycerides
Dose
4 g/day icosapent ethyl (EPA ethyl ester)
Follow-up
4.9 years (median)

25%lower risk of major cardiovascular events

Step 3 of 6
Purified EPA

JELIS, 20073

Who
Japanese adults with high cholesterol, on statins
Dose
1.8 g/day EPA ethyl ester
Follow-up
4.6 years (mean)

19%lower risk of heart attacks and related heart problems

Step 4 of 6
Mixed EPA+DHA

STRENGTH, 20204

Who
High-risk adults on statins with raised triglycerides and low HDL
Dose
4 g/day omega-3 carboxylic acids (EPA+DHA)
Follow-up
42 months (median), stopped early as no benefit was likely

No difference in major cardiovascular events

Step 5 of 6
Mixed EPA+DHA

OMEMI, 20215

Who
Adults aged 70–82 after a recent heart attack, 95% on statins
Dose
1.8 g/day (930 mg EPA + 660 mg DHA)
Follow-up
2 years

No difference in major cardiovascular events

Step 6 of 6

The pattern

Both purified EPA trials sit entirely inside the gold zone: lower risk of major cardiovascular events.

Both mixed EPA+DHA trials cross the "no difference" line: no proven benefit.

The results

What "25% lower risk" means

  • 8,179adults
  • 4.9 yrsmedian follow-up
  • 100%on statins2

Placebo + statin

22 in 100 had a major cardiovascular event

22.0% of 4,090 people

Purified EPA + statin

17 in 100 had a major cardiovascular event

17.2% of 4,089 people

25%

Relative risk reduction

Compared with placebo, the risk of a major cardiovascular event was 25% lower (hazard ratio 0.75).

Lower risk was seen across individual outcomes in REDUCE-IT2

  • 20%Cardiovascular death
  • 31%Heart attack
  • 28%Stroke
  • 35%Urgent procedures to reopen arteries
  • 32%Hospital stay for unstable angina

Relative reductions vs placebo. "Major cardiovascular events" here means: death from heart disease, heart attack, stroke, procedures to reopen arteries, or a hospital stay for unstable angina (worsening chest pain).

JELIS: the earlier result from Japan, at a lower dose

18,645 Japanese adults on statins took 1.8 g of purified EPA a day or no EPA. After 4.6 years, heart attacks and related heart problems occurred in 2.8% with EPA and 3.5% without, a 19% relative reduction.3

Why they differ

Why didn't mixed omega-3 work the same way?

Scientists are still studying this. These are the leading explanations in the published research, not settled facts.

  • EPA and DHA are different molecules

    They have different shapes and effects. In a head-to-head study, DHA raised LDL cholesterol by about 8%, while purified EPA did not raise it.6

  • They behave differently in cell membranes

    EPA sits straight and stable in the membrane and helps protect it from oxidation. DHA makes membranes more fluid and has less of this protective effect.6

  • How much EPA reaches the blood

    In REDUCE-IT, the EPA level reached in the blood appeared to matter for benefit. Mixed products deliver less EPA per gram, so blood levels may stay lower.6

  • EPA helps switch off inflammation

    The body turns EPA into compounds that help inflammation settle down once it has done its job. Mixed products supply less EPA for this pathway.6

How EPA works

Five ways EPA acts on your arteries

EPA does more than lower triglycerides. Research points to a network of effects inside the artery wall and the blood.9

A cut-away artery. Fat particles float in the blood (1), the wall shows inflammation (2), a plaque has a teal protective cap (3), the inner lining is highlighted (4) and platelets drift past (5). 1 2 3 4 5
  1. Lowers harmful blood fats

    EPA reduces the triglyceride-rich particles that carry cholesterol into artery walls.

    Triglycerides−21.5%
    VLDL cholesterol−24.4%
    Non-HDL cholesterol−13.6%
    Apolipoprotein B−9.3%

    ANCHOR, 4 g/day vs placebo, 12 weeks7

  2. Calms inflammation

    Inflammation in the artery wall drives plaque growth. EPA lowered two inflammation markers.

    hsCRP−22.0%
    Lp-PLA2−19.0%

    ANCHOR, 4 g/day vs placebo, 12 weeks7

  3. Steadies plaque and membranes

    EPA settles into cell membranes and helps block oxidation of cholesterol particles. In a heart-scan study, plaque grew more slowly with EPA.

    Total plaque growth, EPA15%
    Total plaque growth, placebo26%

    EVAPORATE, 4 g/day, 9-month scans8; membrane effects6

  4. Supports the artery lining

    EPA helps the inner lining make nitric oxide, which lets blood vessels relax and widen normally.

    Laboratory and clinical studies9

  5. Makes platelets less sticky

    EPA reduces platelet clumping and the clot-promoting signal thromboxane A2.

    Laboratory and clinical studies9

Key takeawayLowering triglycerides alone does not fully explain the benefit seen in REDUCE-IT. Researchers think these effects work together, which may be why purified EPA lowered heart problems beyond what its triglyceride effect would predict.9

Safety

Safety and precautions

Purified EPA was generally well tolerated in the studies. These are the points to know before you start.

  • Irregular heartbeat

    In REDUCE-IT, slightly more people taking EPA were hospitalised for an irregular heartbeat (atrial fibrillation or flutter): 3.1% vs 2.1% on placebo.2 Tell your doctor or pharmacist if you have had an irregular heartbeat.

  • Bleeding

    Serious bleeding occurred in 2.7% with EPA vs 2.1% with placebo, a difference that was not statistically significant.2 If you take blood thinners or antiplatelet medicines such as aspirin or clopidogrel, check with your doctor or pharmacist first.

  • Fish or shellfish allergy

    EPA comes from fish oil. Use caution and speak to a pharmacist if you have a known fish or shellfish allergy.

  • Keep taking your prescribed medicines

    In the studies, EPA was taken together with statins, not instead of them. Do not stop or change any medicine without talking to your doctor.

  • Ask before you start

    Speak with your doctor or pharmacist before starting any supplement, especially if you have a heart condition or take other medicines.

Important information

For healthcare professionals only. This page is intended for registered healthcare professionals and is not for public distribution.

The clinical studies described here (REDUCE-IT, JELIS, STRENGTH, OMEMI, ANCHOR and EVAPORATE) were conducted with other omega-3 products, including prescription purified EPA (icosapent ethyl). None of these studies was conducted with PURO Ikosa-EPA, and their results should not be taken as results of Ikosa-EPA.

PURO Ikosa-EPA is a health supplement. It contains purified EPA in ethyl ester form.